All News

cost.healthcare.jpg

Colchicine Approval Took a Huge Toll on CMS

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
gout.podagra.jpg

Pegloticase in Severe Refractory Gout

Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
food healthy unhealthy beer alcohol salt

The folly of dietary restriction in contemporary gout?

Richard Conway, MBBChBAO, PhD

Gout has historically been considered a disease of the financially rich, rich in diet, and rich in alcohol.

Read Article
ACR Mon

ACR20 - Day 4 Report

Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
Febuxostat bad for the heart? Not so FAST: Dr. Jeffrey Curtis ( @RADoctor) #ACR20 https://t.co/8YFjGslJ7E

Links:

Dr. John Cush RheumNow ( View Tweet)

Comorbidities in Gout with Dr. Nicola Dalbeth https://t.co/RfXfk1MnWj https://t.co/X01lbf5fm7

Links:

Dr. John Cush RheumNow ( View Tweet)
Pipeline Therapies for Urate Lowering: Dr. Michael Pillinger #ACR20 https://t.co/M3ahjjZWK8 https://t.co/Ipc0nowK2t

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group

Dr. John Cush RheumNow ( View Tweet)

Listen as Dr. Petryna ( @DrPetryna) reviews several pegloticase-related abstracts presented at the #ACR20 meeting. https://t.co/TBi1uRPXG0 https://t.co/wAUNr4mq1v

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @Janetbirdope : Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/T81eo3CGjq

Links:

Dr. John Cush RheumNow ( View Tweet)

Auckland-based rheumatologist Dr. Nicola Dalbeth discusses improving responses to the use of Pegloticase, including abstracts #0677 and #0952 presented at #ACR20. https://t.co/xeiMYLZEQa https://t.co/a4RJ6BrNgn

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg

Links:

Dr. John Cush RheumNow ( View Tweet)
Video report from GCAN: Gout, Urate and the repositioning of innate immunity. NYU's Dr. Michael Pillinger promises deeper looks at #ACR20 activity regarding gout, but starts out reporting data from GCAN. https://t.co/PBglAlK4Dg https://t.co/OrPnCPHylD

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Bella Mehta reviews five gout-related abstracts presented at #ACR20 https://t.co/xTaw4HkD0c https://t.co/KVsVwJv3Fy

Links:

Dr. John Cush RheumNow ( View Tweet)
The #ACR20 convergence highlighted a shift in gout management and uric acid lowering therapy (ULT). Read more about mitigating immunogenicity when using uricase therapies as ULT in an article by Dr. Alexa Meara ( @lexmeara) https://t.co/5AfyFhJGqp https://t.co/Sv1BiI0Uwd

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/KfsFFX7z0D

Links:

Dr. John Cush RheumNow ( View Tweet)
Advanced Imaging for Crystal Arthritis: Which Test is Best? Dr. Nicola Dalbeth examines abstracts #0647 and #1542 involving imaging studies for crystal arthritis at #ACR20 https://t.co/g9wAJDPqrG https://t.co/28IcQORmFb

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/lNuzra5Raw

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×